Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure
Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure
复制标题
替米沙坦和吲达帕胺预防中国正常高血压人群的代谢紊乱
DOI：
10.1038/hr.2014.148
复制
发表时间：
2014-10
影响因子：
5.4
通讯作者：
Zhang, Wei
中科院分区：
文献类型：
--
作者：
Tang, Mengxiong;Zhong, Ming;Lu, Fanghong;Zhang, Wei
正常高血压被认为是与代谢紊乱相关的1期高血压的前兆。本研究旨在探讨正常高值血压的药物治疗是否会影响代谢，尤其是在腹部肥胖患者中，以及两种抗高血压药物替米沙坦和吲达帕胺的药物经济学。正常高值血压受试者被随机分配接受替米沙坦、吲达帕胺或安慰剂治疗3年。指导所有受试者在整个研究期间改变生活方式以降低血压。共有221例受试者被随机分配至替米沙坦组，213例接受吲达帕胺组，230例接受安慰剂组。干预3年后，替米沙坦组和吲达帕胺组的血压均较对照组低（P< 0.05），替米沙坦组的FPG在干预前2年较对照组低（P< 0.05），腹型肥胖者3组间无特征性差异（P> 0.05）。替米沙坦组和吲达帕胺组代谢综合征发生率显著降低（P< 0.05），但仅替米沙坦组腹型肥胖发生率显著降低（P< 0.05）。对于相似的降压作用，替米沙坦的采购成本比吲达帕胺高约1.86倍。替米沙坦和吲达帕胺干预正常高值血压似乎是可行的，并降低了代谢综合征的风险。替米沙坦更有效，而吲达帕胺有更好的药物经济学效益。
High-normal blood pressure is considered a precursor of stage 1 hypertension that is associated with metabolic disorders. This study aims to investigate whether the pharmacologic treatment of high-normal blood pressure affects metabolism, especially in abdominally obese individuals, and the pharmacoeconomics of two antihypertensive agents, telmisartan and indapamide. Subjects with high-normal blood pressure were randomly assigned to receive telmisartan, indapamide or placebo for 3 years. All the subjects were instructed to modify their lifestyle to reduce blood pressure throughout the study. A total of 221 subjects were randomly assigned to telmisartan, 213 to indapamide and 230 to placebo. After the 3-year intervention, blood pressure was lower in the telmisartan and indapamide groups (P< 0.05), FPG in the telmisartan group was lower during the first 2 years (P< 0.05) and no characteristic differences were found in those with abdominal obesity among the three groups (P> 0.05). The percentage of subjects with metabolic syndrome was significantly decreased in the telmisartan and indapamide groups (P< 0.05), but was only significantly decreased in the telmisartan group for subjects with abdominal obesity (P< 0.05). The acquisition cost for telmisartan was~ 1.86 times higher than for indapamide for a similar antihypertensive effect. The intervention for high-normal blood pressure with telmisartan and indapamide appeared to be feasible and reduced the risk of metabolic syndrome. Telmisartan was more effective, whereas indapamide had better pharmacoeconomic benefits.
登录
查看更多内容
糖尿病前期成年人的高素质前和相关心血管风险特征的患病率。
影响因子：
4.5
作者：
Ganguly, Shyam Sundar;Al-Shafaee, Mohammed Ali;Bhargava, Kamlesh;Duttagupta, Kalyan Kanti
通讯作者：
Duttagupta, Kalyan Kanti
影响因子：
4.7
作者：
Zhang WH;Zhang L;An WF;Ma JL
通讯作者：
Ma JL
影响因子：
5.4
作者：
Cooper, Jennifer N.;Fried, Linda;Tepper, Ping;Barinas-Mitchell, Emma;Conroy, Molly B.;Evans, Rhobert W.;Brooks, Maria Mori;Woodard, Genevieve A.;Sutton-Tyrrell, Kim
通讯作者：
Sutton-Tyrrell, Kim
影响因子：
158.5
作者：
Yusuf, Salim;Teo, Koon K.;Anderson, Craig
通讯作者：
Anderson, Craig
DOI：
10.1016/j.jvs.2008.06.009
发表时间：
2008
期刊：
The New England Journal of Medicine
影响因子：
--
作者：
J. Marin-Neto
通讯作者：
J. Marin-Neto